Revvity在2025年第四季度的盈利和收入预测中超过预期，并提升了2026年的指引，推动了其股价。 Revvity beat earnings and revenue forecasts for Q4 2025 and raised 2026 guidance, boosting its stock.

Revvity Inc.报告的2025年第四季度结果比预期的2025年第四季度要强,调整后的收入为每股1.70美元,收入7.72亿美元,超过了预测。 Revvity Inc. reported stronger-than-expected fourth-quarter 2025 results, with adjusted earnings of $1.70 per share and revenue of $772 million, surpassing forecasts. 该公司提出了2026年的指导意见,预测每股5.35至5.45美元的收入,29.6亿美元至29.9亿美元的收入,均高于分析师的估计。 The company raised its 2026 guidance, projecting earnings of $5.35 to $5.45 per share and revenue of $2.96 billion to $2.99 billion, both above analyst estimates. 增长受诊断和生命科学需求驱动,制药部门的实力也支持了这些需求。 Growth was driven by demand in diagnostics and life sciences, supported by pharmaceutical sector strength. 宣布后股价在市场前交易中上升。 The stock rose in pre-market trading following the announcement.